FHTX
Foghorn Therapeutics Inc.
NASDAQ · Healthcare · Biotechnology · US
$4.92
+1.03%Next report
Analyst consensus
- Next report date
- Nov 4, 2026
- EPS estimate
- -$0.22
- Revenue estimate
- $7.1M
Latest reported
- Last report date
- Aug 6, 2026
- EPS actual
- -$0.10
- EPS estimate
- -$0.24
- Revenue actual
- $16.1M
- Revenue estimate
- $6.8M
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 7
- EPS misses (12Q)
- 4
- EPS in line (12Q)
- 1
- Avg surprise (4Q)
- +11.5%
- Revenue beats (12Q)
- 5
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 4, 2026